Inhibikase Therapeutics(IKT)
WILMINGTON, DE
BiotechnologyFocus: Therapeutic Vaccines
Inhibikase Therapeutics is a life sciences company focused on Therapeutic Vaccines.
Infectious DiseasesVaccines
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
Imatinib Mesylate
CMLClinical Trials (1)
NCT05623774A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg
Phase 1IkT-001Pro
Pulmonary Arterial Hypertension (PAH)Clinical Trials (1)
NCT06643143A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH)
Phase 2Phase 3
Clinical Trials (1)
NCT07365332An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 3 clinical trials
SEC Filings: 2 available
Financials (FY2024)
Revenue
$261K111%
R&D Spend
$14M(5228%)13%
Net Income
-$19MCash
$9M